Ibritumomab tiuxetan.
Riley
Mary Beth
MB
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. m-riley3@northwestern.edu
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000451:nursing / Q000628:therapy*; D008297:Male; D008991:Monitoring, Physiologic; D016499:Radioimmunotherapy / Q000379:methods*; D018570:Risk Assessment; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C422802:ibritumomab tiuxetan